Rani Therapeutics (RANI) Fundamental Analysis: Revenue, Earnings & Valuation

0.57 / 10

Underperform

Fundamental rating is Underperform, scoring 0.6/10. Strengths include solid interest coverage and inventory turnover, but high current‑liabilities‑to‑total‑liabilities (74%) and low long‑term‑debt‑to‑working‑capital (0.11) drag quality. Overall fundamentals are weak and guarded.

Analysis Checks(5/10)

Revenue-MV

Value-0.28

Score1/3

Weight132.86%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value58.85

Score2/3

Weight3.67%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-30.50%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value74.05

Score1/3

Weight-42.69%

1M Return-1.69%

PB-ROE

Value1.77

Score0/3

Weight90.12%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.11

Score0/3

Weight-116.22%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-31.01%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value58.85

Score2/3

Weight1.49%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-29.31%

1M Return-1.13%

Asset-MV

Value-0.49

Score0/3

Weight121.59%

1M Return4.00%

Is RANI undervalued or overvalued?

RANI scores 0.57/10 on fundamentals and holds a Premium valuation at present. Backed by its -131.87% ROE, -2507.65% net margin, -3.06 P/E ratio, 2.19 P/B ratio, and 57.14% earnings growth, these metrics solidify its Underperform investment rating.